Loading data
DOLENYSE
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 9.17 bn USD | 8.48 bn USD | 8.25 bn USD | 8.02 bn USD | 5.94 bn USD |
| Cost of revenue | 8.46 bn USD | 7.76 bn USD | 7.55 bn USD | 7.42 bn USD | 5.6 bn USD |
| Gross profit | 714.31 m USD | 717.72 m USD | 694.17 m USD | 599.88 m USD | 344 m USD |
| Research and development expense | 9.2 m USD | 8.9 m USD | 9 m USD | 9.2 m USD | 3.8 m USD |
| Selling, general and administrative expense | 495.48 m USD | 474.06 m USD | 473.9 m USD | 436.19 m USD | 323.19 m USD |
| Operating profit | 222.97 m USD | 280.56 m USD | 272.16 m USD | 175.27 m USD | -8.69 m USD |
| Interest expense | 66.54 m USD | 72.26 m USD | 81.11 m USD | 56.37 m USD | 24.99 m USD |
| Income tax expense | 71 m USD | 75.65 m USD | 43.59 m USD | -25.6 m USD | -10.98 m USD |
| Net income (reported basis) | 51.32 m USD | 125.51 m USD | 124.06 m USD | 86.5 m USD | -7.22 m USD |
| Net income attributable to common shareholders | — | — | — | 86.5 m USD | -7.22 m USD |
| Basic earnings per share | 0.54 USD/share | 1.32 USD/share | 1.31 USD/share | 0.91 USD/share | -0.1 USD/share |
| Diluted earnings per share | 0.53 USD/share | 1.32 USD/share | 1.3 USD/share | 0.91 USD/share | -0.1 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.